Recently it has been shown that CSF levels of Aβ1-42, total tau, and phosphorylated-tau proteins define a biomarker signature that is diagnostic for AD and appears to predict conversion from MCI to AD [2–6]. This evidence concerns the gene MAPT and Alzheimer disease.